Pierre Meulien | Executive Director
Innovative Medicines Initiative

Pierre Meulien, Executive Director, Innovative Medicines Initiative

Pierre Meulien is currently President and Chief Executive Officer (CEO) of Genome Canada, a not-for-profit organisation that connects ideas and people across public and private sectors to find new uses for genomics and invests in large-scale science and technology to fuel innovation in key sectors, including health. While at Genome Canada, he succeeded in securing significant funding from the Government of Canada and leveraged further funds through partnerships. He also developed the Genomics Innovation Network to keep Canada at the cutting edge of genomics-based technologies.
 
Before joining Genome Canada in 2010, Pierre Meulien served as Chief Scientific Officer for Genome British Columbia, where he promoted the organisation's scientific strategy. Prior to that, he was founding CEO of the Dublin Molecular Medicine Centre (now Molecular Medicine Ireland) which linked the three medical schools and six teaching hospitals in Dublin to build a critical mass in molecular medicine and translational research. While in this role he served as the Irish representative on the committee that would eventually become the IMI States Representatives Group.
 
Pierre Meulien also has experience of working in industry, having worked at Aventis Pasteur in Canada and France, and at French biotechnology company Transgene. He has a PhD in molecular biology from the University of Edinburgh and worked as a post-doctoral researcher at the Institut Pasteur.

Appearances:



Precision 2018 Day 1 @ 11:40

Advancing innovation in personalised medicine through public private partnerships: The innovative medicines Initiative

  • Technology in the post human genome world is driving new disease taxonomies of disease and therefore new pathways for intervention
  • For some complex diseases like Alzheimer’s Disease, Type 2 Diabetes or Cancer, early stage developments can be achieved with lower risk and lower costs through PPPs
  • Patient engagement at early stages of R&D is critical for overall success
  • Bringing all stakeholders to the table including health economists, regulators, payers as well as Academics, Clinicians, SMEs, Patients and industry players is crucial for dealing with complex disease

Precision 2018 Day 1 @ 14:50

Panel: Funding precision medicine – how to fund your projects

  • What are investors most likely to find compelling in an elevator pitch?
  • Is it the science or the team that attracts capital?
  • How can I obtain access to funding sources?
  • What are the benefits and drawbacks of each capital source?

back to speakers